logo
Dennis Prager sets talk-radio return following a severe spinal cord injury

Dennis Prager sets talk-radio return following a severe spinal cord injury

Yahoo24-03-2025
Dennis Prager, the conservative talk radio host who has been off the air since suffering a debilitating fall in November, will return in June.
Prager, whose nationally syndicated show aired locally from noon to 3 p.m. on AM 870 the Answer before his injury, will come back to host the third hour of that time slot starting June 3, Salem Media announced last week.
"I'm really feeling much better, as you can hear," the author of "The Rational Bible" said in a voice recording played during a March 7 health-update video featuring son David Prager and Prager University Chief Executive Marissa Streit. "My voice is practically normal, which is really exciting, because I intend to go back on radio. ... And my beloved son — one of my beloved sons — my beloved son David is here with me and I can't tell you how much he has done for me. ... OK everybody, looking forward to being with you often."
Read more: Wendy Williams wants 'to move on with my life' despite guardianship: How she got here
At the time that recording was played, Dennis Prager was 15 weeks post-injury. Before his fall, he'd had spinal fusion surgery that resulted in a "pretty stiff situation" with his back, Streit said in a Feb. 14 video update. He hit his head when he fell but suffered no brain injury, she said.
The spinal cord was another story. "It was not severed, but it was injured, and was injured at the top of his spinal cord, at the area of C3 and C4 that also controls his diaphragm," Streit said, noting that Prager could not move below his shoulders at the time.
"He is talking a lot to people in the rehab facility that he's at right now," David Prager, chief development officer for Prager U, said in the same February video. Nonprofit Prager U bills itself as a creator of "free educational content promoting American values." "He's all there. He's 100% there. When you hear him on the radio, you'll say he hasn't skipped a beat."
Read more: Beyond Joy Reid: MSNBC makes major schedule changes as it prepares for NBC News split
Dennis Prager is still undergoing "extensive" rehab, Salem Media said in its release.
"Dennis may have some physical limitations at the moment, but his wit, wisdom, insights and passion are as strong and as clear as ever and we are delighted at his spirit and resolve to return to his audience,' Phil Boyce, Salem's senior vice president of spoken word, said in the release. 'We want Dennis to remain a part of the Salem family and want his millions of loyal fans to continue to hear his voice.'
When Prager returns to radio, it won't be on the exact same show that he left. Salem Media announced last week that "The Charlie Kirk Show," hosted by the founder of the conservative Turning Point USA student movement, will take over Prager's affiliate stations — including 870 AM — beginning next Monday.
"Affiliates of Charlie will continue to get the Kirk show with no interruption, and affiliates of Dennis will soon get Charlie Kirk as a strong and able replacement," Boyce said in the release. The two men had been broadcasting live at the same time of day before Prager fell.
Get notified when the biggest stories in Hollywood, culture and entertainment go live. Sign up for L.A. Times entertainment alerts.
This story originally appeared in Los Angeles Times.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

Yahoo

time18 minutes ago

  • Yahoo

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

Yahoo

timean hour ago

  • Yahoo

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Solve the daily Crossword

AARP endorses bill to prevent upcoding in Medicare Advantage
AARP endorses bill to prevent upcoding in Medicare Advantage

The Hill

time6 hours ago

  • The Hill

AARP endorses bill to prevent upcoding in Medicare Advantage

In a statement Thursday, AARP noted that upcoding is expected to increase care costs for Medicare Advantage enrollees by $40 billion this year. The No UPCODE Act was introduced by Sens. Bill Cassidy (R-La.) and Jeff Merkley (D-Ore.) earlier this year. The bill would disincentivize upcoding by developing a risk-adjustment model using two years of diagnostic data as opposed to one, limiting the use of unrelated medical conditions when estimating the cost of care, and bridging the gap between how patients on Medicare Advantage and traditional Medicare are assessed. In a letter to Cassidy and Merkley, AARP senior vice president for government affairs Bill Sweeney wrote, 'While many Medicare beneficiaries appreciate the flexibility and ease of use that MA provides, we are concerned that upcoding leads to both inflated payments to insurance plans and higher premiums for American seniors.' 'These resources would be better spent strengthening Medicare, such as by providing dental, hearing, and vision coverage,' Sweeney added. 'This bill addresses a problem both Republicans and Democrats have labeled as waste, fraud, and abuse. AARP agrees the No UPCODE Act protects seniors by preserving benefits and eliminating waste,' Cassidy said in a statement Thursday. 'When companies upcode, taxpayers foot the bill and patients get nothing. That's wrong.' While the Trump administration has railed against waste, fraud and abuse in Medicare and Medicaid, the vast majority of Medicare payments are made properly. As KFF found in its analysis of fiscal year 2024 payments, 94.4 percent of Medicare Advantage payments were made properly, with improper Medicare payments totaling $54.3 billion.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store